Compare RPAY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPAY | TNXP |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.5M | 198.6M |
| IPO Year | 2018 | 2008 |
| Metric | RPAY | TNXP |
|---|---|---|
| Price | $3.86 | $13.38 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.53 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 440.0K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $309,261,000.00 | $13,107,000.00 |
| Revenue This Year | $12.54 | $558.11 |
| Revenue Next Year | $4.66 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $2.30 | $11.60 |
| 52 Week High | $5.90 | $69.65 |
| Indicator | RPAY | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 46.32 |
| Support Level | $3.35 | $13.32 |
| Resistance Level | $5.23 | $20.36 |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 78.90 | 50.64 |
Repay Holdings Corp is a payments technology company. It provides integrated payment processing solutions to industry-oriented vertical markets in which businesses or other organizations have specific transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments. The company generates majority of its revenue from Consumer Payments segment.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.